Skip to main content

Table 6 Comparison between the switch and pirfenidone-naïve groups

From: Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis

 

Switch-group (n = 30)

Pirfenidone-naïve group (n = 64)

p value

Just before initiation of pirfenidone

Just before initiation of nintedanib

Characteristics

 Age

71.0 [67.0, 75.0]

72.0 [68.0, 74.8]

72.0 [65.8, 75.3]

0.903*

 Gender (male/female)

24 / 6

24 / 6

53 / 11

0.778*

 Physique

  Height (cm)

165 [158, 169]

165 [158, 169]

164 [160, 170]

0.958*

  Body weight (kg)

61.4 [59.2, 66.0]

54.9 [49.7, 64.4]

63.2 [54.2, 73.1]

0.01*

  Body mass index

22.6 [21.0, 24.9]

21.0 [19.0, 23.6]

23.9 [20.7, 26.2]

0.001*

  Body surface area (DuBois, m2)

1.69 [1.62, 1.76]

1.59 [1.48, 1.72]

1.68 [1.54, 1.82]

0.063*

 Lung function test

  Forced vital capacity (L)

2.36 [1.78, 3.52]

1.68 [1.34, 1.99]

2.21 [1.74, 2.66]

0.001*

  % Forced vital capacity (%)

62.5 [51.0, 76.6]

52.9 [43.7, 69.7]

67.7 [55.9, 79.0]

0.001*

  % DLco (%)

58.4 [46.7, 65.7]

44.2 [40.9, 58.5]

54.8 [47.6, 67.9]

0.009*

Nintedanib

 Administration period (month)

–

5.30 [2.84, 11.8]

6.13 [3.02, 14.5]

0.415

 Discontinue within 6 months

–

16 (53.3%)

21 (32.8%)

0.072

 Adverse events

  AST/ALT elevation

–

19 (63.3%)

46 (71.9%)

0.475

  Diarrhea

–

14 (46.7%)

34 (53.1%)

0.659

  Anorexia

–

14 (46.7%)

14 (21.9%)

0.028

  Weight loss

–

6 (20.0%)

6 (9.3%)

0.188

  Nausea

–

2 (6.7%)

11 (17.1%)

0.213

  Fatigue

–

3 (10.0%)

5 (7.8%)

0.707

  1. Categorical data are presented as numbers (percentages), whereas continuous data are presented as medians (interquartile ranges). *p values were calculated by comparing the baseline characteristics of the switch-group just before nintedanib initiation and the baseline characteristics of the pirfenidone-naïve group. Fisher’s exact test was used to compare categorical data, and the Mann–Whitney U test was used to compare continuous data
  2. Abbreviations: DLCO diffusing capacity for lung carbon monoxide, AST aspartate aminotransferase, ALT alanine aminotransferase